Description of screening programme. The Fetal Anomaly Screening Programme recommend a mid-pregnancy scan which is undertaken between 18+0 to 20+6 weeks of pregnancy to screen for major fetal anomalies. The examination should be undertaken in accordance with the requirements of the FASP guidance (Anatomical Base Menu and Fetal Cardiac Protocol) xxxxx://xxx.xxx.xx/government/publications/fetal-anomaly-screening-programme- handbook . The first scan is an early pregnancy scan performed from 8+0 weeks gestation and is used mainly for dating the pregnancy and confirming viability. The second scan is undertaken between 18+0 to 20+6 weeks of pregnancy and screens for major structural abnormalities. The 11 auditable conditions currently screened for are: • Anencephaly; • Open xxxxx bifida; • Cleft lip; • Diaphragmatic hernia; • Gastroschisis; • Exomphalos; • Serious cardiac abnormalities; • Bilateral renal agenesis; • Lethal skeletal dysplasia; • Xxxxxxx’ syndrome (Trisomy 13) • Patau’s syndrome (Trisomy 18) The ultrasound scan appointment should incorporate pre-scan counselling, the ultrasound examination, post-scan counselling and reporting. The time allocation for appointments to meet these requirements for a xxxxxxxxx pregnancy is a minimum of thirty (30) minutes and for a multiple pregnancy is forty five (45) minutes. In delivering a national screening programme and to ensure national consistency the local Provider is expected to fulfil the following, in conjunction with guidance from the national programme where appropriate and as detailed in the standard and policies available On xxxxx://xxx.xxx.xx/government/collections/nhs-population-screening-programme- standards • work to nationally agreed common standards and policies • be required to implement and support national IT developments • use materials provided by the national screening programme, e.g. leaflets, training media and protocols for their use • be required to respond to national action/lessons such as change of software, equipment supplier, techniques • work with NHS England in reporting on and resolving safety incidents • provide data and reports against programme standards, key performance indicators (KPIs), and quality indicators as required by the national screening programme • take part in quality assurance processes and implement changes recommended by QA including urgent suspension of services if required • implement and monitor failsafe procedures and continuously ensure quality • work with bordering Providers to ensure that...
Description of screening programme. The Programme comprises a number of elements which the provider is expected to achieve: identifying and inviting all eligible people with diabetes for screening at regular intervals (i.e. call/recall) taking digital images of the eyes of the person with diabetes grading the digital images of the eyes of the person with diabetes providing surveillance clinics with slit lamp biomicroscopy assessments providing surveillance clinics using digital imaging ensuring people with diabetes with referable eye disease are referred to appropriate Hospital Eye Services/Treatment Services undertaking internal Quality Assurance (QA) providing clinical oversight and governance for the Programme In accordance with NHS Screening Programmes’ standards and protocols the provider is expected to fulfil the following work to nationally agreed NDESP standards, guidance, policies and pathway implement and support national IT developments use NHS Screening Programme materials and the protocols for their use provide timely and accurate performance data respond to national action/lessons such as change of software, supplier, techniques work with NHS England and NHS Screening Programmes QA team in reporting on and resolving incidents and serious incidents report against standard Key Performance Indicators (KPIs) and quality indicators as required take part in QA processes implement failsafe procedures according to national guidance and continuously ensure quality ensure that there is sufficient resource to provide routine (currently annual) digital screening to the defined population work with commissioners to ensure uptake is maximised and there is equity of access to the service for all people with diabetes. ensure the workforce is qualified and meeting all NDESP standards The programme interfaces with and is supported by a number of other services (e.g. primary care, diabetology, hospital eye services and IT support). In order to ensure that the programme delivers a co-ordinated and seamless service in a multi-provider environment, the screening provider must work with any providers that support or deliver other elements of the complete pathway or provide interfacing services and must work to common standards, policies and protocols.
Description of screening programme. The UK NSC policy on newborn hearing screening is that all eligible newborn babies in England should be offered screening for bilateral permanent hearing impairment (sensorineural or permanent conductive). Screening should be offered to all babies up to 3 months of age although ideally screening should be performed within days of birth. Those older than 3 months of age, or otherwise not eligible for screening, should be considered for referral to audiology. In delivering a national programme and to ensure national consistency, the local provider is expected to fulfil the following, in conjunction with guidance from the national screening programme where appropriate and as detailed in the programme guidance. • work to nationally agreed programme standards, policies, recommended guidance and pathways • be required to implement and support national IT developments • be required to respond to national actions/lessons such as change of software, equipment supplier, techniques • ensure appropriate governance structures are in place • implement and monitor checks and audit procedures and continuously ensure quality and safety • work with bordering providers to ensure that handover of results or patients is smooth and robust • provide data and reports against programme standards, key performance indicators (KPIs), and quality indicators as required • take part in quality assurance processes and implement changes recommended by QA including urgent suspension of services if required • work with NHS England and NHS Improvement in reporting, investigating and resolving screening incidents and implement agreed actions in accordance to the Managing Safety Incidents in NHS Screening Programmes • provide evidence that all healthcare professionals access and complete appropriate training to maintain continuous professional development and competency • use materials provided by the national programme, e.g. information, leaflets, training resources and guidance • participate in evaluation of the screening programme
Description of screening programme. Screening for Down’s, Xxxxxxx’ and Patau’s syndromes is part of the NHS Fetal Anomaly Screening Programme (FASP). In line with NICE guidance (Clinical guideline 62 Antenatal care June 2010 xxxx://xxx.xxxx.xxx.xx/guidance/CG62 all pregnant women should be offered an early ultrasound scan to determine gestational age. The NHS screening programme’s recommended screening tests are gestation dependent, and are as follows: • between 10+0 and 14+1 weeks of pregnancy the combined test, which consists of a nuchal translucency scan and a blood test that measures two specific maternal biochemical markers for use in screening for Down’s, Xxxxxxx’ and Patau’s syndromes. • between 14+2 to 20+0 weeks the quadruple test which measures four maternal biochemical markers for use in screening for Down’s syndrome only To complete the ultrasound component of this screening strategy, the scan appointment should allocate time to incorporate pre-scan counselling, the ultrasound examination, post- scan counselling and reporting. The time allocation for appointments to meet these requirements is a minimum of twenty (20) minutes. The results of either test give an individual risk assessment to the woman on the possibility that her baby/ies will have Down’s, Xxxxxxx’ or Patau’s syndromes. If the risk of having a term pregnancy affected with any of these syndromes is 1 in 150 or higher, the pregnancy is regarded as higher risk and the woman will be offered a prenatal diagnostic (PND) test. In January 2016 the UK NSC recommended an evaluative roll out of NIPT to assess what impact it would have on the existing NHS Fetal Anomaly Screening Programme. If the screening test shows that the chance of having a baby with Down’s, Xxxxxxx’ and Patau’s syndromes is higher than 1 in 150, this is called a higher-risk result. Currently, women who have a higher risk result have the option of having an invasive diagnostic test (amniocentesis or CVS). The proposed change is for Non-Invasive Prenatal Testing to be offered to women who are deemed at higher risk following the current primary screen. NIPT is not diagnostic and an invasive diagnostic test is still required to receive a definitive diagnosis. Through 2017-18 the FASP programme will undertake a scoping exercise to plan how NIPT might be integrated into the current screening pathway as an additional option for women with a higher risk result. This will require education and training of all staff contributing to the screening pathway and developm...
Description of screening programme. The UK National Screening Committee (UK NSC) policy for NIPE is that all eligible babies will be offered the NIPE screen. The screen should be offered within 72 hours of birth and then again at 6-8 weeks of age. The universal offer of screening facilitates early detection of congenital defects of the heart, hips, eyes and testes. Any abnormalities suspected or detected and any clinical concerns identified will lead to a prompt referral for early clinical assessment by the relevant clinical expert. In delivering a national screening programme and to ensure national consistency the local provider is expected to fulfil the following, in conjunction with guidance from the national screening programme where appropriate and as detailed in national policy and standards work to nationally agreed standards and policies be required to implement and support national IT developments be required to respond to national actions such as change of IT software, equipment supplier and techniques ensure appropriate governance structures are in place implement and monitor failsafe procedures and continuously ensure quality and safety work with bordering providers to ensure that handover of results or patients is smooth and robust provide data and reports mapped against programme standards, key performance indicators, and quality indicators as required take part in quality assurance (QA) processes and implement changes recommended by QA including urgent suspension of services if required work with the NHS in reporting , investigating and resolving screening safety incidents and implement agreed actions ensure all health care professionals access and complete appropriate training to maintain continuous professional development and competency use materials provided by the national screening programme, e.g. information leaflets, e-learning and other training resources, and policies to support local service delivery participate in evaluation of the screening programme
